Discussion about this post

User's avatar
Jordy Stravers's avatar

The interesting finding in most of this research is that resilience turns out to be an organisational property rather than a network property. Two companies can run the same dual-sourcing strategy and the same inventory policy, and one still gets caught out, because in the second one somebody owns supplier qualification end to end and knows what a change at a tier-two supplier actually triggers.

That is sharper in pharma than almost anywhere else. Switching an API source or a packaging component is not a procurement decision, it is a regulatory variation with comparability work and possibly a filing behind it, so your real lead time is set by qualification and change control capacity, not by logistics. Networks are usually mapped long before anyone checks whether the people who can execute a supplier change are in place. More on that here: https://www.sire-search.com/life-science-supply-chain-consulting-grip-op-een-complexe-gereguleerde-keten/ (Dutch)

No posts

Ready for more?